To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | 195615-83-9 |
| Synonyms: | 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;AE37;AE38;AVex-73 |
| SMILES: | CN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1 |
| Formula: | C19H23NO |
| M.Wt: | 281.392 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1]. |
| In Vivo: | Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1]. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1]. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1]. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1]. Animal Model: Female Mecp2tm1.1Bird/J HET (C57 background) mice[1] Dosage: 10 mg/kg, 30 mg/kg Administration: Oral administration, daily, for 6.5 weeks Result: Reverse the deficits observed in the HET animals. |
| References: | [1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|